Biopharmaceutical giant BioMarin has announced an agreement to acquire Amicus Therapeutics for $4.8 billion. This transaction represents the largest in the company’s 28-year history, signaling a bold shift in business development strategy under new leadership.
deal details and market reaction BioMarin will pay $14.50 per share for Amicus, representing a 46% premium over the target’s 30-day average price.
- Stock impact: Following the announcement, BioMarin’s share price surged by 18%, reflecting strong investor confidence in the strategic merits of the deal.
- Timeline: The acquisition is expected to close in the second quarter of 2026.
strategic product portfolio Through the acquisition of Amicus, BioMarin gains two high-growth commercial assets:
- Galafold: A treatment for Fabry disease, which generated $458 million in 2024. With an estimated 6,000 diagnosed but untreated patients, the drug holds significant market potential.
- Pombiliti-Opfolda: A combination therapy for Pompe disease, approved in late 2023 and currently expanding its global footprint.
Beyond the commercial stage, BioMarin also acquires the U.S. rights to DMX-200, a potential first-in-class molecule currently in Phase 3 development for a rare kidney disease.
vision and growth expectations BioMarin leadership believes that leveraging their established commercial infrastructure in nearly 80 countries will accelerate the growth of the newly acquired assets. Both Galafold and Pombiliti-Opfolda are projected to reach “blockbuster” status, with potential peak sales of $1 billion each.
This acquisition helps BioMarin diversify its revenue streams as its flagship product, Voxzogo, nears potential market competition. It also reaffirms the company’s commitment to dominating the enzyme replacement therapy sector for rare diseases worldwide.
Source: https://www.fiercepharma.com/pharma/biomarin-pulls-rare-disease-marriage-48b-buyout-amicus